Targeted Complement Inhibitor for CNS Injury Reperfusion

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for stroke, traumatic brain injury, and spinal cord injury are limited by the need for immediate intervention and the secondary damage caused by cerebral reperfusion, which can lead to further tissue damage and disability.

Innovation Solution

A composition comprising a targeted inhibitor molecule that inhibits complement signaling, specifically designed to bind to Annexin IV or phospholipids, combined with a thrombolytic agent such as t-PA, to treat central nervous system injuries.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If thrombolytic therapy is administered to treat stroke, then clot dissolution and blood flow restoration are improved, but secondary injury from complement activation and reperfusion damage increases

Engineering Contradiction:

Improveclot dissolution efficiencyVSAvoidreperfusion injury

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces a targeted complement inhibitor as an intermediary agent that specifically binds to activated complement components (C3a, C5a) at the site of reperfusion injury. This mediator blocks the harmful inflammatory cascade triggered by thrombolytic therapy while allowing the thrombolytic agent to continue dissolving clots effectively.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies preliminary anti-action by administering complement inhibitors before or concurrently with thrombolytic therapy to pre-block the complement activation pathway. This preemptive approach prevents the formation of harmful inflammatory mediators before they can cause significant tissue damage, while still allowing clot dissolution to proceed.

Inventive Principle:

Principle #9Preliminary anti-action

2Measurement precision

If treatment is delayed beyond immediate onset to allow for patient assessment and transport, then treatment accuracy is improved, but the effectiveness of stroke treatment decreases due to time-dependent damage progression

Engineering Contradiction:

Improvepatient assessment accuracyVSAvoidtreatment effectiveness

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent employs preliminary action by providing complement inhibition that begins protecting brain tissue from reperfusion injury as soon as the inhibitor is administered, rather than waiting for full patient assessment and thrombolytic preparation. This early protective action maintains treatment effectiveness even when there is a delay in initiating the complete therapy protocol.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent applies beforehand cushioning by introducing complement inhibitors that create a protective buffer against incoming reperfusion damage during the time delay period. This cushioning effect absorbs the harmful impacts of delayed treatment, preserving neuronal tissue and maintaining treatment reliability even when assessment and transport take longer than ideal.

Inventive Principle:

Principle #11Beforehand cushioning (Prior cushioning)

3Object-affected harmful factors

If complement inhibition is applied to reduce reperfusion injury, then tissue damage is reduced, but the treatment complexity increases due to combination therapy requirements

Engineering Contradiction:

Improvetissue damageVSAvoidtreatment protocol complexity

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent merges two therapeutic agents (thrombolytic and complement inhibitor) into a coordinated combination therapy protocol where the complement inhibitor is administered concurrently with or immediately before the thrombolytic agent. This merging approach reduces tissue damage through synergistic protection while managing complexity through standardized co-administration guidelines and unified treatment protocols.

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination of complement inhibition and thrombolytic therapy reduces infarct volume, improves functional recovery, and extends the treatment window for central nervous system injuries, potentially leading to better motor and cognitive outcomes.

Implementation Method 1

the targeting portion comprises an antibody or fragment thereof that specifically binds to Annexin IV, a post-translational modification found on Annexin IV and other proteins, or a phospholipid

Methodology Applied

Scientific EffectSpecific binding:

Implementation Method 2

the thrombolytic agent is t-PA

Methodology Applied

Scientific EffectThrombolysis:

Data Source

PatentUS20250144190A1Compositions and methods for treating central nervous system injury

Publication Date: 2025.05.08 THE MEDICAL UNIV OF SOUTH CAROLINA

AI summary

The present invention describes compositions and method for improving outcomes after injury to the central nervous system wherein complement signaling is activated. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a therapeutic agent comprising a targeted inhibitor molecule comprising a targeting portion and an inhibitor portion, wherein the molecule inhibits complement, and wherein therapeutic agent is administered in combination with rehabilitation therapy or thrombolytic agent.